166 related articles for article (PubMed ID: 28787411)
41. Enasidenib: First Global Approval.
Kim ES
Drugs; 2017 Oct; 77(15):1705-1711. PubMed ID: 28879540
[TBL] [Abstract][Full Text] [Related]
42. Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
Zhang CC; Yan Z; Pascual B; Jackson-Fisher A; Huang DS; Zong Q; Elliott M; Fan C; Huser N; Lee J; Sung M; Sapra P
Neoplasia; 2018 Jan; 20(1):1-11. PubMed ID: 29172076
[TBL] [Abstract][Full Text] [Related]
43. Midostaurin: First Global Approval.
Kim ES
Drugs; 2017 Jul; 77(11):1251-1259. PubMed ID: 28612232
[TBL] [Abstract][Full Text] [Related]
44. [Acute myeloid leukemia].
Nannya Y; Kurokawa M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():496-500. PubMed ID: 23513890
[No Abstract] [Full Text] [Related]
45. Midostaurin + Chemo Ups AML Survival.
Cancer Discov; 2016 Feb; 6(2):OF2. PubMed ID: 26739883
[TBL] [Abstract][Full Text] [Related]
46. Midostaurin for the treatment of acute myeloid leukemia.
Patnaik MM
Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
[TBL] [Abstract][Full Text] [Related]
47. Synergistic effect of all‑trans retinoic acid in combination with protein kinase C 412 in FMS-like tyrosine kinase 3-mutated acute myeloid leukemia cells.
Chi HT; Ly BT; Vu HA; Sato Y; Dung PC; Xinh PT
Mol Med Rep; 2015 May; 11(5):3969-75. PubMed ID: 25592076
[TBL] [Abstract][Full Text] [Related]
48. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
[TBL] [Abstract][Full Text] [Related]
49. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
Cooper BW; Kindwall-Keller TL; Craig MD; Creger RJ; Hamadani M; Tse WW; Lazarus HM
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):428-432.e2. PubMed ID: 25776192
[TBL] [Abstract][Full Text] [Related]
50. 57th American Society of Hematology Annual Meeting.
Smith LL
Lancet Oncol; 2016 Feb; 17(2):142. PubMed ID: 26687594
[No Abstract] [Full Text] [Related]
51. Acute Macular Neuroretinopathy Associated With an Oral FLT3 Inhibitor.
Liu Y; Haq Z; Pasricha ND; Bever GJ
JAMA Ophthalmol; 2020 Oct; 138(10):1104-1106. PubMed ID: 32761105
[No Abstract] [Full Text] [Related]
52. [FLT3 inhibitors for acute myeloid leukemia].
Kiyoi H
Nihon Rinsho; 2014 Jun; 72(6):1035-41. PubMed ID: 25016800
[TBL] [Abstract][Full Text] [Related]
53. Emerging treatments in acute myeloid leukemia: current standards and unmet challenges.
Percival ME; Estey E
Clin Adv Hematol Oncol; 2017 Aug; 15(8):632-642. PubMed ID: 28949951
[TBL] [Abstract][Full Text] [Related]
54. [Possibility of targeting FLT3 kinase for the treatment of leukemia].
Kiyoi H
Rinsho Ketsueki; 2005 Mar; 46(3):187-97. PubMed ID: 16447713
[No Abstract] [Full Text] [Related]
55. Gemtuzumab Ozogamicin Makes a Comeback.
Cancer Discov; 2017 Nov; 7(11):1208. PubMed ID: 28931515
[TBL] [Abstract][Full Text] [Related]
56. FLT3 inhibitors for acute myeloid leukemia.
Lancet JE
Clin Adv Hematol Oncol; 2015 Sep; 13(9):573-5. PubMed ID: 26452187
[No Abstract] [Full Text] [Related]
57. Treatment of AML: resurrection for gemtuzumab ozogamicin?
Estey E
Lancet; 2012 Apr; 379(9825):1468-9. PubMed ID: 22482941
[No Abstract] [Full Text] [Related]
58. [FLT3 kinase inhibitors for the treatment of acute leukemia].
Kiyoi H
Rinsho Ketsueki; 2010 Jun; 51(6):384-9. PubMed ID: 20622483
[No Abstract] [Full Text] [Related]
59. Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro.
Heidel F; Lipka DB; Mirea FK; Mahboobi S; Grundler R; Kancha RK; Duyster J; Naumann M; Huber C; Böhmer FD; Fischer T
Br J Haematol; 2009 Mar; 144(6):865-74. PubMed ID: 19183186
[TBL] [Abstract][Full Text] [Related]
60. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
